Humana's Stock Gets Upgrade from Bernstein Amid Mixed Outlook: Navigating Risks and Rewards

Humana Inc. (NYSE: HUM) has recently caught the attention of Wall Street, receiving a noteworthy upgrade from Bernstein analysts on Tuesday. The firm has elevated its rating from Market-Perform to Outperform, showcasing a shift in sentiment despite Humana facing a few hurdles recently.

The analysts expressed renewed optimism regarding Humana's future prospects, highlighting a blend of market factors that suggest a more promising path ahead. According to Bernstein, this upgrade hinges on their assessment that risks have already been factored into the stock's current valuation, alongside an enhanced outlook for the sector as a whole. They also pointed out potential catalysts that could drive the stock higher.

One of the key areas where Bernstein sees improvement is in Humana's operating landscape for its Medicare Advantage plans. The uncertainties that have clouded previous forecasts, particularly relating to STARS ratings and repricing strategies, appear to be clarifying, helping to stabilize investor confidence. Furthermore, Bernstein noted that the stock’s price reduction has created a more favorable balance between upside opportunities and downside risks, particularly in light of possible takeover interests and trends in Pharmacy Benefit Manager (PBM) outsourcing.

However, it’s not all sunshine and rainbows; Bernstein has revised its financial projections, taking into account Humana's recent announcement regarding a significant drop in STARS ratings. The analysts now predict diminished STARS ratings for 2026, estimating that only around 25% of members will find themselves in plans rated four stars or higher. This development is expected to negatively affect earnings. Nevertheless, Bernstein believes that strategic pricing adjustments and efforts to engage and migrate members could effectively alleviate about two-thirds of the impact on the Medical Loss Ratio (MLR).

Consequently, Bernstein anticipates an approximate 24% decrease in adjusted earnings per share (EPS) for the fiscal year 2026. Reflecting these updated expectations, the price target for Humana has been revised down to $308 from an earlier target of $405. In addition, the target multiple has been adjusted downward to 16.0x next-twelve-month EPS from 18.0x, acknowledging a potential delay in earnings growth due to the challenges associated with STARS ratings.